In the present study, we evaluated the expression of four cancer stem cell markers CD44, CD133, SOX2, Nanog in a large cohort of palatal MEC patients and identified some effective combinations of markers that have prognostic value for palatal MEC patients. This evidence concerns the gene PROM1 and mucoepidermoid carcinoma.